Skip to main content

Table 2 Associations between TNF-α and TNFRSF1B genotypes and overall survival of NSCLC patients

From: TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy

Genotypes

No. of patients

No. of Deaths

MST (months)

Crude HR (95% CI)

Adjusted HR (95% CI)a

Adjusted P a

TNF-α -308 G>A (rs1800629)

   GG

163

112 (68.7)

23.5

1.00

1.00

 

   AG

56

39 (69.6)

23.2

1.04 (0.72-1.50)

0.95 (0.65-1.40)

0.802

   AA

6

4 (66.7)

18.1

1.18 (0.44-3.21)

1.10 (0.39-3.11)

0.859

   AG+AA

61

43 (70.5)

23.1

1.05 (0.74-1.50)

0.96 (0.67-1.40)

0.849

   AG+GG

219

151 (68.9)

23.4

1.00

1.00

 

   AA

6

4 (66.7)

18.1

1.17(0.43-3.16)

1.11 (0.40-3.13)

0.840

TNF-α -1031T>C (rs1799964)

   TT

137

95 (69.3)

23.4

1.00

1.00

 

   CT

77

50 (64.9)

22.1

0.96 (0.68-1.35)

0.89 (0.62-1.28)

0.542

   CC

11

10 (90.9)

23.1

1.28 (0.67-2.46)

1.41 (0.70-2.87)

0.341

   CT+CC

88

60 (68.2)

23.1

1.00 (0.72-1.38)

0.95 (0.68-1.34)

0.785

   CT+TT

214

145 (67.8)

23.4

1.00

1.00

 

   CC

11

10 (90.9)

23.1

1.30(0.68-2.47)

1.46 (0.73-2.94)

0.289

TNFRSF1B +676 T>G (rs1061622)

   TT

124

85 (68.5)

23.4

1.00

1.00

 

   GT

90

65 (72.2)

21.8

1.10 (0.80-1.52)

1.19 (0.84-1.69)

0.323

   GG

11

5 (45.5)

41.1b

0.36 (0.14-0.88)

0.38 (0.15-0.94)

0.037

   GT+GG

101

70 (69.3)

23.2

0.96 (0.70-1.31)

1.01 (0.72-1.42)

0.937

   GT+TT

214

150 (70.1)

22.7

1.00

1.00

 

   GG

11

5 (45.5)

41.1b

0.34 (0.14-0.84)

0.35 (0.14-0.88)

0.026

TNFRSF1B -1709A>T (rs652625)

   AA

207

144 (69.6)

23.2

1.00

1.00

 

   AT

15

9 (60.0)

27.8

0.86 (0.44-1.69)

0.85 (0.42-1.71)

0.649

   TT

3

2 (66.7)

15.1

0.94 (0.23-3.82)

1.02 (0.23-4.47)

0.976

   AT+TT

18

11 (61.1)

26.7

0.88 (0.47-1.62)

0.87 (0.46-1.67)

0.685

   AT+AA

222

153 (68.9)

23.4

1.00

1.00

 

   TT

3

2 (66.7)

15.1

0.95 (0.24-3.85)

1.05 (0.24-4.58)

0.946

TNFRSF1B +1663A>G(rs1061624)

   AA

67

46 (68.7)

23.4

1.00

1.00

 

   AG

89

63 (70.8)

21.1

1.06 (0.73-1.53)

0.98 (0.68-1.43)

0.921

   GG

62

41 (66.1)

28.1

0.84 (0.56-1.26)

0.79 (0.52-1.20)

0.269

   AG+GG

151

104 (68.9)

24.0

1.03(0.73-1.46)

0.96 (0.67-1.37)

0.824

   AG+AA

156

109 (69.9)

22.7

1.00

1.00

 

   GG

62

41 (66.1)

28.1

0.84 (0.59-1.20)

0.81 (0.56-1.18)

0.275

  1. MST: median survival time; HR: hazard ratio
  2. aAdjusted for age, gender, ethnicity, smoking status, tumor histology, KPS, tumor stage, node status, application of chemotherapy and radiotherapy dose.
  3. bMean survival time was provided when MST could not be calculated.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us